Resumo Objetivo Analisar os desfechos de uma coorte de pacientes com câncer de endométrio (CE) e histologias de alto risco atendida no Instituto Nacional do Câncer (INCA) entre 2010 e 2016. Materiais e Métodos Foram revisados prontuários de pacientes com histologias de alto risco de CE em qualquer estágio cadastradas no INCA entre 2010 e 2016 para realizar uma análise descritiva clínica e demográfica e avaliar os resultados em termos de recorrência e sobrevida. Resultados De 2010 a 2016, 2.145 pacientes com CE foram cadastradas e atendidas no INCA, e 466 tinham histologias de alto grau e atendiam aos critérios de inclusão. A média de idade das pacientes foi de 65 anos, 44,6% eram brancas, e 90% tinham performance status de 0 ou 1. A histologia mais comum foi endometrioide de alto grau (31,1%), seguida de carcinoma seroso (25,3%), misto (20,0%), carcinossarcoma (13,5%) e carcinoma de células claras (9,4%). Considerando o estadiamento da Fédération Internationale de Gynécologie et d'Obstétrique (Federação Internacional de Ginecologia e Obstetrícia, FIGO, em francês) de 2018, 44,8%, 12,4%, 29,8% e 12,9% apresentaram estágios I, II, III ou IV, respectivamente. Idade (> 60 anos), mais de 50% de mioinvasão, estágio avançado, performance status ruim, histologias serosas e carcinossarcoma, e tratamento adjuvante foram fatores independentes associados à sobrevida livre de recorrência e sobrevida global na análise multivariada. Conclusão Os achados atuais reforçam os dados internacionais que demonstram o prognóstico ruim desses tumores, principalmente para as histologias serosas e carcinossarcomas e para estágios avançados, com menor sobrevida e altas taxas de recorrência à distância, independentemente do estágio da FIGO. A terapia adjuvante foi associada a melhor sobrevida. (CE (INCA 201 2145 2 145 2.14 46 inclusão 6 anos 446 44 44,6 brancas 90 1 31,1%, 311 31,1% , 31 (31,1%) 25,3%, 253 25,3% 25 3 (25,3%) 20,0%, 200 20,0% 20 (20,0%) 13,5% 135 13 5 (13,5% 9,4%. 94 9,4% . 9 4 (9,4%) dObstétrique d Obstétrique Federação Obstetrícia FIGO francês 2018 448 8 44,8% 124 12 12,4% 298 29 29,8 129 12,9 I II IV respectivamente > ( anos) 50 mioinvasão avançado multivariada tumores avançados distância 214 14 2.1 44, 31,1 (31,1% 25,3 (25,3% 20,0 (20,0% 13,5 (13,5 9,4 (9,4% 44,8 12,4 29, 12, 21 2. 31, (31,1 25, (25,3 20, (20,0 13, (13, 9, (9,4 (31, (25, (20, (13 (9, (31 (25 (20 (1 (9 (3 (2

Abstract Objective To analyze the outcomes of a cohort of patients with high-risk histologies of endometrial cancer (EC) treated at Instituto Nacional de Câncer (National Cancer Institute, INCA, in Portuguese), in Brazil. Materials and Methods We reviewed the medical records of patients with high-risk histologies of EC in any stage registered at INCA between 2010 and 2016 to perform a clinical and demographic descriptive analysis and to evaluate the outcomes in terms of recurrence and survival. Results From 2010 to 2016, 2,145 EC patients were registered and treated at INCA, and 466 had high-grade histologies that met the inclusion criteria. The mean age of the patients was 65 years, 44.6% were Caucasian, and 90% had a performance status of 0 or 1. The most common histology was high-grade endometrioid (31.1%), followed by serous carcinoma (25.3%), mixed (20.0%), carcinosarcoma (13.5%), and clear cell carcinoma (9.4%). Considering the 2018 Fédération Internationale de Gynécologie et d'Obstétrique (International Federation of Gynecology and Obstetrics, FIGO, in French) staging system, 44.8%, 12.4%, 29.8%, and 12.9% of the patient were in stages I, II, III or IV respectively. Age (> 60 years), more than 50% of myoinvasion, higher stage, poor performance status, serous and carcinosarcoma histologies, and adjuvant treatment were independent factors associated with recurrence-free survival (RFS) and overall survival (OS) in the multivariate analysis. Conclusion The current findings reinforced the international data showing poor outcomes of these tumors, especially for serous and carcinosarcomas and tumors with advanced stages, with shorter survival and high recurrence rates in distant sites, independently of the FIGO stage. Adjuvant therapy was associated with better survival. highrisk risk (EC National Institute Portuguese, Portuguese , Portuguese) Brazil 201 2145 2 145 2,14 46 highgrade grade criteria 6 years 446 44 44.6 Caucasian 90 1 31.1%, 311 31.1% 31 (31.1%) 25.3%, 253 25.3% 25 3 (25.3%) 20.0%, 200 20.0% 20 (20.0%) 13.5%, 135 13.5% 13 5 (13.5%) 9.4%. 94 9.4% . 9 4 (9.4%) dObstétrique d Obstétrique International Obstetrics French system 448 8 44.8% 124 12 12.4% 298 29 29.8% 129 12.9 I II respectively > ( years) 50 myoinvasion recurrencefree free RFS (RFS OS (OS sites 214 14 2,1 44. 31.1 (31.1% 25.3 (25.3% 20.0 (20.0% 13.5 (13.5% 9.4 (9.4% 44.8 12.4 29.8 12. 21 2, 31. (31.1 25. (25.3 20. (20.0 13. (13.5 9. (9.4 29. (31. (25. (20. (13. (9. (31 (25 (20 (13 (9 (3 (2 (1

ABSTRACT Introduction: Acute lymphoblastic leukemia (ALL) presents a poor prognosis in adults. The adoption of pediatric protocols has been changing this scenario, especially for adolescents and young adults (AYA). Objective and method: We aimed to evaluate a consecutive series of patients treated at the State Institute of Hematology of Rio de Janeiro between 2012 and 2020, focusing on the AYA subgroup. Result: The B-ALL was the most frequent subtype (81.6%) and AYA, the predominant age group (57.7%). The median overall survival (OS) was 9.4 months. High early mortality was observed and sepsis was the main cause of death. Better OS results were noted in AYA, in comparison to over 39y (13.3 × 6.2 months, respectively), the Berlin-Frankfurt-Münster (BFM) being the protocol of choice in this group. Conclusion: The use of the pediatric protocol seems to improve the OS of AYA, however, high rates of deaths from infection were observed, demonstrating the need for advances in the Brazilian public system clinical support. Introduction ALL (ALL scenario AYA. . (AYA) method 201 2020 subgroup Result BALL B 81.6% 816 81 6 (81.6% 57.7%. 577 57.7% 57 7 (57.7%) (OS 94 9 4 9. months death y 13.3 133 13 3 (13. 62 2 6. respectively, respectively , respectively) BerlinFrankfurtMünster Berlin Frankfurt Münster BFM (BFM Conclusion however support (AYA 20 202 81.6 8 (81.6 57.7 5 (57.7% 13. 1 (13 81. (81. 57. (57.7 (1 (81 (57. ( (8 (57 (5

Abstract Merkel cell carcinoma is a rare skin cancer with neuroendocrine differentiation. The risk factors include sun exposure, advanced age, immunosuppression (such as transplant recipients, patients with lymphoproliferative neoplasms, or patients with HIV), and Merkel cell polyomavirus infection. Clinically, Merkel cell carcinoma appears as a cutaneous or subcutaneous plaque or nodule, but this tumor diagnosis is rarely made clinically. Therefore, histopathology and immunohistochemistry are usually necessary. Primary tumors without evidence of metastases are treated with complete surgical excision and appropriate surgical margins. The presence of occult metastasis in a lymph node is frequent and a sentinel lymph node biopsy should be performed. Postoperative adjuvant radiotherapy increases local tumor control. Recently, agents that block the PD-1/PD-L1 pathway have shown objective and durable tumor regression in patients with advanced solid malignancies. The first anti-PD-L1 antibody used in patients with Merkel cell carcinoma was avelumab, but pembrolizumab and nivolumab have also shown efficacy. This article describes the current state of knowledge of the epidemiology, diagnosis, and staging of Merkel cell carcinoma, as well as new strategies for its systemic treatment. differentiation exposure age such recipients neoplasms HIV, HIV , HIV) infection Clinically nodule clinically Therefore necessary margins performed control Recently PD1/PDL1 PD1PDL1 PDPDL PD 1/PD L1 1 L PD-1/PD-L malignancies antiPDL1 antiPDL anti anti-PD-L avelumab efficacy epidemiology treatment PD1 PDL1 PDL PD1/PDL PD1PDL 1PD

ABSTRACT The standard treatment for locally advanced cervical cancer (CC) is chemoradiotherapy. Once the bladder receives part of the radiation, a typical inflammatory condition that configures radiation-induced cystitis may develop. Chronic radiation-induced cystitis is commonly characterized by the bladder new submucosal vascularization, which is typically fragile and favors hematuria. The current study aims to investigate if Hypoxia-Induced Factor (HIF-1α) and its transcriptional target Vascular Endothelial Growth Factor A (VEGF-A) could be a primary pathway leading to increased submucosal vascularization. HIF-1α and VEGF-A mRNA levels in bladder core biopsies from CC patients treated with radiotherapy versus untreated (non-irradiated) patients were analyzed using a droplet digital polymerase chain reaction technology. Gene expression results showed that HIF-1α and VEGF-A had no significant differences between bladder samples from patients previously irradiated and untreated patient samples. However, a direct relationship between the degree of late morbidity and the expression of HIF-1α and VEGF-A has been demonstrated. Despite the lack of statistical significance precludes a definitive conclusion, the data presented herein suggests that further studies investigating the role of HIF-1α in bladder neovascularization in radiation-induced cystitis are highly recommended.